Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease

A type 1 diabetic patient with unilateral active thyroid‐related eye disease was intolerant to systemic steroid therapy due to uncontrollable blood sugar levels. She was treated with low‐dose methotrexate monotherapy, which resulted in a marked improvement of her condition with no adverse events....

Descripción completa

Detalles Bibliográficos
Autores principales: Elnahry, Ayman G., Talbet, Joseph H., Elnahry, Gehad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271214/
https://www.ncbi.nlm.nih.gov/pubmed/34267921
http://dx.doi.org/10.1002/ccr3.4559
_version_ 1783720951201923072
author Elnahry, Ayman G.
Talbet, Joseph H.
Elnahry, Gehad A.
author_facet Elnahry, Ayman G.
Talbet, Joseph H.
Elnahry, Gehad A.
author_sort Elnahry, Ayman G.
collection PubMed
description A type 1 diabetic patient with unilateral active thyroid‐related eye disease was intolerant to systemic steroid therapy due to uncontrollable blood sugar levels. She was treated with low‐dose methotrexate monotherapy, which resulted in a marked improvement of her condition with no adverse events.
format Online
Article
Text
id pubmed-8271214
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82712142021-07-14 Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease Elnahry, Ayman G. Talbet, Joseph H. Elnahry, Gehad A. Clin Case Rep Clinical Images A type 1 diabetic patient with unilateral active thyroid‐related eye disease was intolerant to systemic steroid therapy due to uncontrollable blood sugar levels. She was treated with low‐dose methotrexate monotherapy, which resulted in a marked improvement of her condition with no adverse events. John Wiley and Sons Inc. 2021-07-09 /pmc/articles/PMC8271214/ /pubmed/34267921 http://dx.doi.org/10.1002/ccr3.4559 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Images
Elnahry, Ayman G.
Talbet, Joseph H.
Elnahry, Gehad A.
Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
title Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
title_full Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
title_fullStr Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
title_full_unstemmed Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
title_short Methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
title_sort methotrexate monotherapy for unilateral moderately active thyroid‐related eye disease
topic Clinical Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271214/
https://www.ncbi.nlm.nih.gov/pubmed/34267921
http://dx.doi.org/10.1002/ccr3.4559
work_keys_str_mv AT elnahryaymang methotrexatemonotherapyforunilateralmoderatelyactivethyroidrelatedeyedisease
AT talbetjosephh methotrexatemonotherapyforunilateralmoderatelyactivethyroidrelatedeyedisease
AT elnahrygehada methotrexatemonotherapyforunilateralmoderatelyactivethyroidrelatedeyedisease

Ejemplares similares